Biohit Oyj
HLSE:BIOBV Stock Report
Biohit Oyj Balance Sheet Health
Financial Health criteria checks 6/6 Biohit Oyj has a total shareholder equity of €10.8M and total debt of €0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are €14.2M and €3.4M respectively.
Key information Interest coverage ratio n/a Cash €5.00m Equity €10.80m Total liabilities €3.40m Total assets €14.20m
Recent financial health updates
Show all updates
First half 2024 earnings: EPS exceeds analyst expectations while revenues lag behind Aug 12
Price target increased by 17% to €2.70 Aug 09
Full year 2023 earnings: EPS and revenues exceed analyst expectations Mar 26
Biohit Oyj's (HEL:BIOBV) Solid Profits Have Weak Fundamentals Feb 22
Consensus EPS estimates increase by 18% Feb 21
Biohit Oyj Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next Feb 17
Full year 2023 earnings: Revenues exceed analyst expectations Feb 16 Biohit Oyj to Report First Half, 2024 Results on Aug 07, 2024 Biohit Oyj Announces Changes in the Management Group
New major risk - Earnings quality Aug 11
First half 2023 earnings: EPS and revenues exceed analyst expectations Aug 11
Biohit Revises Earnings Guidance for 2023 Aug 10
Biohit Oyj Approves Election of Vesa Silaskivi as Members of Board of Directors Jun 15
Full year 2022 earnings released: EPS: €0.04 (vs €0.10 loss in FY 2021) Mar 27
Investor sentiment deteriorates as stock falls 19% Feb 22
Biohit Oyj Provides Earnings Guidance for the Year 2023 Feb 16
Full year 2022 earnings released Feb 16
Biohit Oyj Announces Executive Changes Dec 16 Biohit Oyj to Report Fiscal Year 2022 Final Results on Mar 22, 2023
No independent directors Nov 16
Investor sentiment improved over the past week Nov 08
Investor sentiment improved over the past week Sep 12 Biohit Oyj Appoints Jussi Sorvo as Chief Financial Officer, Effective on September 7, 2022
Biohit Oyj Announces Executive Changes Sep 03
Biohit Oyj Appoints Panu Hendolin as Member of the Management Team Aug 23
First half 2022 earnings released: EPS: €0.06 (vs €0.073 loss in 1H 2021) Aug 15
Biohit Oyj Revises Earnings Guidance for the Year 2022 Aug 05
Companies Like Biohit Oyj (HEL:BIOBV) Are In A Position To Invest In Growth Aug 04
Biohit Oyj Appoints Lea Paloheimo as the Chairman of the Board of Directors Jun 17
Biohit Oyj Elects Kalle Härkönen as Board of Director Jun 16
Less than half of directors are independent Apr 27
Full year 2021 earnings: Revenues in line with analyst expectations Feb 17
Biohit Oyj Provides Earnings Guidance for the Year 2022 Feb 16
Companies Like Biohit Oyj (HEL:BIOBV) Are In A Position To Invest In Growth Feb 09
Biohit Oyj Specifies Financial Guidance for 2021 Feb 09
Biohit Oyj Announces Recent Clinical Validation Study Confirms the Accuracy of the New-Generation GastroPanel Test in Diagnosis of Atrophic Gastritis and Helicobacter Pylori Infection Dec 15
First half 2021 earnings released: €0.073 loss per share (vs €0.15 loss in 1H 2020) Aug 12
Biohit Oyj (HEL:BIOBV) Is In A Strong Position To Grow Its Business Aug 11
President & CEO Semi Korpela has left the company May 26
Biohit Oyj (HEL:BIOBV) Is In A Strong Position To Grow Its Business Apr 13
Full year 2020 earnings released: €0.22 loss per share (vs €0.094 loss in FY 2019) Mar 29
Full year 2020 earnings released: €0.22 loss per share (vs €0.094 loss in FY 2019) Feb 19
We Think Biohit Oyj (HEL:BIOBV) Can Afford To Drive Business Growth Dec 28
New 90-day high: €2.26 Dec 28 Biohit Oyj to Report First Half, 2021 Results on Aug 11, 2021
Biohit Oyj to Report Fiscal Year 2020 Results on Feb 17, 2021 Dec 10
New 90-day low: €1.99 Oct 21
New 90-day low: €2.00 Sep 25 Biohit Oyj Elects Osmo Suovaniemi as the Chairman of the Board of Directors
New 90-day low - €2.14 Sep 05
Financial Position Analysis
Short Term Liabilities: BIOBV's short term assets (€12.9M) exceed its short term liabilities (€3.0M).
Long Term Liabilities: BIOBV's short term assets (€12.9M) exceed its long term liabilities (€400.0K).
Debt to Equity History and Analysis
Debt Level: BIOBV is debt free.
Reducing Debt: BIOBV had no debt 5 years ago.
Debt Coverage: BIOBV has no debt, therefore it does not need to be covered by operating cash flow .
Interest Coverage: BIOBV has no debt, therefore coverage of interest payments is not a concern.
Discover healthy companies Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
